Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company’s Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global... Read More

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds upon body of positive preclinical data demonstrating dose dependent anti-tumor activity and favorable safety profile -Initial safety data anticipated in first half 2026... Read More

Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 Phase 2 ASPEN-Breast evorpacept trial design updated to enable CD47 and HER2 biomarker-driven strategy in a single-arm study; anticipated interim data readout in Q3 2026 ALX2004 Phase 1 clinical trial remains on track to... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its second quarter 2025 financial results and a business update on Tuesday, August 12th, 2025, after market close. The... Read More

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date:... Read More

A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 Trials evaluating the Company’s lead... Read More

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class... Read More

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on... Read More

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a... Read More

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising anti-tumor activity Combination generated complete responses (CR) in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R... Read More

In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab), into a registrational study Company remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent... Read More

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platform ALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientists Company expects to initiate Phase 1 clinical trials of ALX2004 in mid-2025, with initial safety data available in 1H 2026... Read More

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI Presented Phase 1b/2 data demonstrating evorpacept in combination with zanidatamab generates promising anti-tumor activity in advanced breast cancer at SABCS 2024 Announced focused development plan... Read More

Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc ., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. The company will... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The... Read More

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights e vorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trial Greatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs.... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that effective January 21, 2025, the Compensation Committee of the Board of Directors of ALX Oncology granted an inducement stock option... Read More

Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operations Dr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experience Dr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan.... Read More

Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives,... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer, Jason Lettmann, will deliver a company... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of... Read More

Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced that the... Read More

Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical activity in patients with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxtecan-nxki (ENHERTU ® ) Combination therapy was well tolerated with a manageable safety profile consistent with prior experience with each... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc ., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that Jason Lettmann, the Company’s Chief Executive Officer will participate in a fireside chat at the Piper Sandler 36th... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. “Dr. Sandler’s breadth of experience and demonstrated... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We made substantial... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that management will participate in two upcoming investor conferences. 2024 UBS Global Healthcare Conference Format: Fireside... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology’s evorpacept in combination with Jazz Pharmaceuticals’... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today that management will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 17 – 19, 2024. Format: Fireside chat with... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the first patients have been dosed in an arm of the randomized UMBRELLA phase 1/2 clinical study partnered with Sanofi that is evaluating evorpacept in combination with SARCLISA ®... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. “Our team continues to make significant progress in the advancement of our... Read More

Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Company’s clinical program advances SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company... Read More

Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial population In the pre-specified population of patients with fresh... Read More

Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase... Read More

Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”)... Read More

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows: Format: Fireside chat with analyst, Michael Yee and 1x1 Investor... Read More

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We entered the quarter with a great deal of momentum having achieved a key... Read More

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth... Read More

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored trial (“IST”) of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA ®... Read More

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024. Session... Read More

Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R 2 ”) Evorpacept plus R 2 was well tolerated with a safety profile similar to historical R 2 The combination achieved promising initial activity with a best overall response rate (“ORR”) of 94% and a complete response rate (“CRR”) of 83% in patients with indolent R/R B-NHL (R 2 historical CRR... Read More

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “This past year proved to be a profound growth period for ALX... Read More

Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that two clinical abstracts have been accepted... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced today that Jason Lettmann, Chief Executive Officer of ALX Oncology, will present a company overview at the 42 nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. Third Quarter 2023 Highlights and Recent Developments Reported positive... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in three upcoming investor conferences in November. 2023 UBS BioPharma Conference Format: Fireside chat with analyst, Dr. Colin Bristow Date: Wednesday,... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology sold 8,663,793 shares of common stock, which... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology is selling 7,370,690 shares of common stock and, in... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants in this offering will be... Read More

Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment Company to host conference call and webcast today at 8:00 AM EDT SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or... Read More

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3 rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of... Read More

Jason Lettmann appointed as Chief Executive Officer Dr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that Jason Lettmann, a member of the Board of Directors, will... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences. H.C. Wainwright 25 th Annual Global Investment Conference Format: Fireside chat with analyst, Swayampakula... Read More

Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the... Read More

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that evorpacept, a next-generation CD47 blocker, has received orphan drug designation (“ODD”) from the European Commission (“EC”) for the treatment of patients with gastric cancer. This... Read More

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights. “In the first quarter of 2023, we continued to make significant... Read More

SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the initiation of a Phase 2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with liposomal doxorubicin and KEYTRUDA ® (pembrolizumab), Merck’s... Read More

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA... Read More

SOUTH SAN FRANCISCO, Calif. , March 14, 2023 /PRNewswire/ -- ALX Oncology Holdings Inc. , ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic... Read More

SOUTH SAN FRANCISCO, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative (“Quantum Leap”) today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic... Read More

SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided clinical development and operational highlights. “2022 was a productive year for us, with numerous... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV® (enfortumab vedotin-ejfv), an antibody drug... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2023. “2022 marked a successful year of continued clinical and corporate accomplishments for ALX Oncology. Marked by... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at... Read More

Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax ALX Oncology to Host Conference Call on December 13 th at 7:30 a.m. EST SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. , (“ALX Oncology”) (Nasdaq: ALXO),... Read More